mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Major depressive disorder is among the most prevalent forms of mental illness. All currently available antidepressant medications have stemmed from study of the mechanisms of serendipitously discovered drugs, and only 30-50% of patients exhibit remission and frequently at least 3-4 weeks are required for manifestation of significant therapeutic effects. To overcome these drawbacks, discovering novel neuronal mechanisms of pathophysiology of depression as well as more effective treatments are necessary. This review focuses on the metabotropic glutamate (mGlu) receptors and their potential for drug targets for the treatment of depression. In particular, accumulating evidence has indicated the potential importance and usefulness of agents acting on mGlu2/3 and mGlu5 receptors. Preclinical and clinical evidence of mGlu2/3 receptor ligands and mGlu5 receptor antagonists are described. Moreover, their potential in clinic will be discussed in the context of neuronal mechanisms of ketamine, an agent recently demonstrated a robust effect for patients with treatment-resistant depression. This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 2×
“of patients respond to the initial regimen), and approximately 30% of patients are resistant to a series of treatments (Fekadu et al., 2009; Rosenzweig-Lipson et al., 2007; Rush et al., 2006; Trivedi et al., 2006).”
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754 · cited 1×
“Depression represents also a social problem, with the lifetime prevalence rates of depression amounts to 16% in the USA (Kessler et al., 2003) and over 30 million people affected each year in the EU (Wittchen et al., 2011).”
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“Recent studies have shown that ketamine activates mammalian target of rapamycin (mTOR) signaling through the stimulation of AMPA receptors, and implicating mTOR signaling in the antidepressant effects of ketamine (Li et al., 2010, 2011).”
Molecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280 · cited 1×
“The economic burden ofmood disorders is immense, amounting to 100 billion USD in the US and 105 billion Euros in the EU (Greenberg et al., 2003; Andlin-Sobocki et al., 2005), making the mood disorders the most costly group out of all central nervous system (CNS) diseases.”
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 2×
“, 2011) and in treatment-resistant bipolar depression (Diazgranados et al., 2010).”
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Regulation of Neurotransmitter Release by Metabotropic Glutamate Receptors
Cartmell, J., & Schoepp, D. D. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750889.x · Cited by 883
Fone, K. C. F., & Porkess, M. V. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.003 · Cited by 864
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785
Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression
Drevets, W. C. (2000) · Progress in Brain Research · doi:10.1016/s0079-6123(00)26027-5 · Cited by 659 · cited 2×
“particularly in regions of relevance for MDD, such as hippocampus, prefrontal cortex, amygdala, (Drevets, 2000).”
Lu, Y.-M., Jia, Z., Janus, C., Henderson, J. T., Gerlai, R., Wojtowicz, J. M., & Roder, J. C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-13-05196.1997 · Cited by 634
Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex
Covington, H. E., Lobo, M. K., Maze, I., Vialou, V., Hyman, J. M., Zaman, S., LaPlant, Q., Mouzon, E., Ghose, S., Tamminga, C. A., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1731-10.2010 · Cited by 621 · cited 1×
“…stimulation of the medial prefrontal cortex using optogenetic techniques displays a rapid antidepressant effect in a social defeat stress paradigm inmice (Covington et al., 2010), suggesting that activation of glutamatergic transmission may in some brain regions exert an antidepressant action.”
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609 · cited 1×
“However, fenobam binds in the primates to the sites which are not recognized by some of the mGlu5 receptor NAMs (Raboisson et al., 2011), moreover, no significant adverse effects of fenobam in fragile X syndrome were reported (Berry-Kravis et al., 2009; Jacquemont et al., 2011).”
Metabotropic glutamate receptors as novel targets for anxiety and stress disorders
Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411 · cited 1×
“However, fenobam binds in the primates to the sites which are not recognized by some of the mGlu5 receptor NAMs (Raboisson et al., 2011), moreover, no significant adverse effects of fenobam in fragile X syndrome were reported (Berry-Kravis et al., 2009; Jacquemont et al., 2011).”
Efficacy and effectiveness of antidepressants: current status of research
Pigott, H. E., Leventhal, A. M., Alter, G. S., & Boren, J. J. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000318293 · Cited by 347 · cited 1×
“Importantly, meta- analyses suggest that antidepressants are only marginally efficacious compared to placebos, especially at moderate levels of initial depression (Kirsch et al., 2008; Pigott et al., 2010).”
Koike, H., Iijima, M., & Chaki, S. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.05.035 · Cited by 346 · cited 2×
“…effects of MGS0039 and LY341495 were observed both at 30 min and 24 h after the treatment in the TST, and this relatively sustained, but not acute, antidepressant effect of mGlu2/3 receptor antagonists was blocked by pretreatment with rapamycin, an mTOR antagonist (Koike et al., 2011b).”
Self-citationDeakin, J. F. W., Lees, J., McKie, S., Hallak, J. E. C., Williams, S. R., & Dursun, S. M. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.37 · Cited by 311 · cited 2×
“For example, the dorsolateral and dorsomedial regions of prefrontal cortex has been reported to be underactive during aMDDepisodewhereas ventral cortical structures are hyperactivated, and ketamine has been reported to ameliorate these abnormalities as demonstrated by magnetic resonance imaging (Deakin et al., 2008).”
Porter, R. H. P., Jaeschke, G., Spooren, W., Ballard, T. M., Büttelmann, B., Kolczewski, S., Peters, J.-U., Prinssen, E., Wichmann, J., Vieira, E., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089839 · Cited by 308
Deschwanden, A., Karolewicz, B., Feyissa, A. M., Treyer, V., Ametamey, S. M., Johayem, A., Burger, C., Auberson, Y. P., Sovago, J., Stockmeier, C. A., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.09111607 · Cited by 278
Chaki, S., Yoshikawa, R., Hirota, S., Shimazaki, T., Maeda, M., Kawashima, N., Yoshimizu, T., Yasuhara, A., Sakagami, K., Okuyama, S., et al. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.10.009 · Cited by 254
Self-citationA role for AMPA receptors in mood disorders
Alt, A., Nisenbaum, E. S., Bleakman, D., & Witkin, J. M. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.022 · Cited by 238 · cited 2×
“Of note, AMPA receptor potentiators have been reported to exhibit antidepressant effects in animal models of depression (Alt et al., 2006).”
Shirayama, Y., & Chaki, S. (2006) · Current Neuropharmacology · doi:10.2174/157015906778520773 · Cited by 225
Self-citationPotential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S. (2010) · CNS Drugs · doi:10.2165/11533230-000000000-00000 · Cited by 180 · cited 1×
“A considerable number of papers have been published on mGlu receptors and depression/ antidepressant activity (Hashimoto, 2011; Krystal et al., 2010; Palucha and Pilc, 2007; Pilc et al., 2008; Swanson et al., 2005; Wieronska and Pilc, 2009).”
Ketamine as a Novel Antidepressant: From Synapse to Behavior
Murrough, J. W. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.244 · Cited by 172 · cited 2×
“prolonged and potent antidepressant effects in patients with TRD, and reduced suicidal ideation in some clinical studies (Murrough, 2012).”
mTOR activation is required for the antidepressant effects of mGluR2/3 blockade
Dwyer, J. M., Lepack, A. E., & Duman, R. S. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001702 · Cited by 169 · cited 1×
“The involvement of mTOR signaling in the antidepressant effects of mGlu2/3 receptor antagonists has recently been confirmed by the study in which rapamycin blocked the antidepressant effect of LY341495 in the FST (Dwyer et al., 2011).”
Mood disorders: Regulation by metabotropic glutamate receptors
Pilc, A., Chaki, S., Nowak, G., & Witkin, J. M. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.09.021 · Cited by 163
Self-citationJohnson, M. P., Barda, D., Britton, T. C., Emkey, R., Hornback, W. J., Jagdmann, G. E., McKinzie, D. L., Nisenbaum, E. S., Tizzano, J. P., & Schoepp, D. D. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2099-9 · Cited by 156 · cited 6×
“Importantly, the maximal response elicited by THIIC was similar to that observed with imipramine (Fell et al., 2011), suggesting an important role of mGlu2 receptor in the pathophysiology of depression.”
InfluentialMorishima, Y., Miyakawa, T., Furuyashiki, T., Tanaka, Y., Mizuma, H., & Nakanishi, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500914102 · Cited by 148 · cited 2×
“antidepressant-like phenotype in the FST (Morishima et al., 2005), supporting the data obtained from experiments with the use of”
van Hooft, J. A., Giuffrida, R., Blatow, M., & Monyer, H. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-10-03544.2000 · Cited by 141 · cited 1×
“…were shown to be localized predominantly postsynaptically (Lujan et al., 1996) and in the hippocampus and prefrontal cortex, brain regions known to be involved in depression, those receptors are extensively expressed on GABAergic interneurons (van Hooft et al., 2000; Zhou and Hablitz, 1997).”
Koike, H., Iijima, M., & Chaki, S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.034 · Cited by 114 · cited 2×
“…effects of MGS0039 and LY341495 were observed both at 30 min and 24 h after the treatment in the TST, and this relatively sustained, but not acute, antidepressant effect of mGlu2/3 receptor antagonists was blocked by pretreatment with rapamycin, an mTOR antagonist (Koike et al., 2011b).”
Self-citationAMPA potentiator treatment of cognitive deficits in Alzheimer disease
Chappell, A. S., Gonzales, C., Williams, J., Witte, M. M., Mohs, R. C., & Sperling, R. (2007) · Neurology · doi:10.1212/01.wnl.0000260240.46070.7c · Cited by 89 · cited 2×
“psychiatric Inventory score suggested that a number of depressivelike symptoms were improved (Chappell et al., 2007).”
Scaccianoce, S., Matrisciano, F., Del Bianco, P., Caricasole, A., Di Giorgi Gerevini, V., Cappuccio, I., Melchiorri, D., Battaglia, G., & Nicoletti, F. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00027-3 · Cited by 54 · cited 2×
“mGlu2/3 receptors negatively modulate the hypothalamicepituitaryeadrenal axis (Scaccianoce et al., 2003), which is known to be up-regulated in MDD and other stress-related disorders (Mason and Pariante, 2006).”
Self-citation
Cited by
Moriguchi, S., Takamiya, A., Noda, Y., Horita, N., Wada, M., Tsugawa, S., Plitman, E., Sano, Y., Tarumi, R., ElSalhy, M., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0252-9 · Cited by 357
Nasca, C., Xenos, D., Barone, Y., Caruso, A., Scaccianoce, S., Matrisciano, F., Battaglia, G., Mathé, A. A., Pittaluga, A., Lionetto, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216100110 · Cited by 263
Self-citationEmerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity
Gerhard, D. M., Wohleb, E. S., & Duman, R. S. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.016 · Cited by 261
Quiroz, J. A., Tamburri, P., Deptula, D., Banken, L., Beyer, U., Rabbia, M., Parkar, N., Fontoura, P., & Santarelli, L. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0838 · Cited by 133
Yao, N., Skiteva, O., Zhang, X., Svenningsson, P., & Chergui, K. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.239 · Cited by 118
Metadata
- Authors
- Chaki, S., Ago, Y., Palucha-Paniewiera, A., Matrisciano, F., & Pilc, A.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2013-03
- Volume
- 66
- Pages
- 40-52
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2012827629
- Cited by
- 116
- References
- 40
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.